Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2015, Article ID 786362, 17 pages
http://dx.doi.org/10.1155/2015/786362
Review Article

Polycystic Ovary Syndrome: Important Underrecognised Cardiometabolic Risk Factor in Reproductive-Age Women

1Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Clinical Hospital Centre, School of Medicine, University of Zagreb, Petrova 13, 10 000 Zagreb, Croatia
2School of Medicine, Medical Studies in English, University of Zagreb, Šalata 3, 10 000 Zagreb, Croatia

Received 14 December 2014; Accepted 26 March 2015

Academic Editor: Manuel Estrada

Copyright © 2015 Dinka Pavicic Baldani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Bargiota and E. Diamanti-Kandarakis, “The effects of old, new and emerging medicines on metabolic aberrations in PCOS,” Therapeutic Advances in Endocrinology and Metabolism, vol. 3, no. 1, pp. 27–47, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. W. A. March, V. M. Moore, K. J. Willson, D. I. W. Phillips, R. J. Norman, and M. J. Davies, “The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria,” Human Reproduction, vol. 25, no. 2, pp. 544–551, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. J. A. Tomlinson, J. H. Pinkney, P. Evans, A. Millward, and E. Stenhouse, “Screening for diabetes and cardiometabolic disease in women with polycystic ovary syndrome,” British Journal of Diabetes and Vascular Disease, vol. 13, no. 3, pp. 115–123, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. L. K. Hoffman and D. A. Ehrmann, “Cardiometabolic features of polycystic ovary syndrome,” Nature Clinical Practice Endocrinology & Metabolism, vol. 4, no. 4, pp. 215–222, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Teede, A. Deeks, and L. Moran, “Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan,” BMC Medicine, vol. 8, article 41, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Diamanti-Kandarakis and A. Dunaif, “Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications,” Endocrine Reviews, vol. 33, no. 6, pp. 981–1030, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. L. J. Moran, M. L. Misso, R. A. Wild, and R. J. Norman, “Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis,” Human Reproduction Update, vol. 16, no. 4, pp. 347–363, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. H. S. Randeva, B. K. Tan, M. O. Weickert et al., “Cardiometabolic aspects of the polycystic ovary syndrome,” Endocrine Reviews, vol. 33, no. 5, pp. 812–841, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. F. Orio Jr., S. Palomba, T. Cascella et al., “Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 9, pp. 4588–4593, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. H. F. Escobar-Morreale, M. Luque-Ramírez, and F. González, “Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis,” Fertility and Sterility, vol. 95, no. 3, pp. 1048.e2–1058.e2, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Moran and H. Teede, “Metabolic features of the reproductive phenotypes of polycystic ovary syndrome,” Human Reproduction Update, vol. 15, no. 4, pp. 477–488, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. T. M. Barber and S. Franks, “Genetics of polycystic ovary syndrome,” Frontiers of Hormone Research, vol. 40, pp. 28–39, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. U. Unluturk, A. Harmanci, C. Kocaefe, and B. O. Yildiz, “The genetic basis of the polycystic ovary syndrome: a literature review including discussion of PPAR-γ,” PPAR Research, vol. 2007, Article ID 49109, 23 pages, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Carmina, R. S. Legro, K. Stamets, J. Lowell, and R. A. Lobo, “Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet,” Human Reproduction, vol. 18, no. 11, pp. 2289–2293, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Carmina, “Metabolic syndrome in polycystic ovary syndrome,” Minerva Ginecologica, vol. 58, no. 2, pp. 109–114, 2006. View at Google Scholar · View at Scopus
  16. R. P. Kauffman, T. E. Baker, V. M. Baker, P. DiMarino, and V. D. Castracane, “Endocrine and metabolic differences among phenotypic expressions of polycystic ovary syndrome according to the 2003 Rotterdam consensus criteria,” The American Journal of Obstetrics and Gynecology, vol. 198, no. 6, pp. 670.e1–670.e10, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Carmina, N. Napoli, R. A. Longo, G. B. Rini, and R. A. Lobo, “Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS,” European Journal of Endocrinology, vol. 154, no. 1, pp. 141–145, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. D. P. Baldani, L. Skrgatic, M. S. Goldstajn, H. Vrcic, T. Canic, and M. Strelec, “Clinical, hormonal and metabolic characteristics of polycystic ovary syndrome among obese and nonobese women in the Croatian population,” Collegium Antropologicum, vol. 37, no. 2, pp. 465–470, 2013. View at Google Scholar · View at Scopus
  19. A. Dunaif, K. R. Segal, W. Futterweit, and A. Dobrjansky, “Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome,” Diabetes, vol. 38, no. 9, pp. 1165–1174, 1989. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Moran, M. Arriaga, G. Rodriguez, and S. Moran, “Obesity differentially affects phenotypes of polycystic ovary syndrome,” International Journal of Endocrinology, vol. 2012, Article ID 317241, 7 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Sam, “Obesity and polycystic ovary syndrome,” Obesity Management, vol. 3, no. 2, pp. 69–73, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. R. J. Norman, L. Masters, C. R. Milner, J. X. Wang, and M. J. Davies, “Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome,” Human Reproduction, vol. 16, no. 9, pp. 1995–1998, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. D. A. Ehrmann, R. B. Barnes, R. L. Rosenfield, M. K. Cavaghan, and J. Imperial, “Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome,” Diabetes Care, vol. 22, no. 1, pp. 141–146, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. A. D. Attie and P. E. Scherer, “Adipocyte metabolism and obesity,” Journal of Lipid Research, vol. 50, pp. S395–S399, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Lind, “Circulating markers of inflammation and atherosclerosis,” Atherosclerosis, vol. 169, no. 2, pp. 203–214, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. F. Gonzalez, K. Thusu, E. Abdel-Rahman, A. Prabhala, M. Tomani, and P. Dandona, “Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome,” Metabolism: Clinical and Experimental, vol. 48, no. 4, pp. 437–441, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Samy, M. Hashim, M. Sayed, and M. Said, “Clinical significance of inflammatory markers in polycystic ovary syndrome: their relationship to insulin resistance and body mass index,” Disease Markers, vol. 26, no. 4, pp. 163–170, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Faulds, M. Rydén, I. Ek, H. Wahrenberg, and P. Arner, “Mechanisms behind lipolytic catecholamine resistance of subcutaneous fat cells in the polycystic ovarian syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 5, pp. 2269–2273, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. F. Orio Jr., G. Matarese, S. di Biase et al., “Exon 6 and 2 peroxisome proliferator-activated receptor-gamma polymorphisms in polycystic ovary syndrome,” Journal of Clinical Endocrinology & Metabolism, vol. 88, no. 12, pp. 5887–5892, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. A. L. Hirschberg, S. Naessén, M. Stridsberg, B. Bystrom, and J. Holte, “Impaired cholecystokinin secretion and disturbed appetite regulation in women with polycystic ovary syndrome,” Gynecological Endocrinology, vol. 19, no. 2, pp. 79–87, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. S. McCluskey, C. Evans, J. H. Lacey, J. M. Pearce, and H. Jacobs, “Polycystic ovary syndrome and bulimia,” Fertility and Sterility, vol. 55, no. 2, pp. 287–291, 1991. View at Google Scholar · View at Scopus
  32. S. Jahanfar, J. A. Eden, and T. V. Nguyent, “Bulimia nervosa and polycystic ovary syndrome,” Gynecological Endocrinology, vol. 9, no. 2, pp. 113–117, 1995. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Naessén, K. Carlström, L. Garoff, R. Glant, and A. L. Hirschberg, “Polycystic ovary syndrome in bulimic women—an evaluation based on the new diagnostic criteria,” Gynecological Endocrinology, vol. 22, no. 7, pp. 388–394, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Sundblad, M. Landén, T. Eriksson, L. Bergman, and E. Eriksson, “Effects of the androgen antagonist flutamide and the serotonin reuptake inhibitor citalopram in bulimia nervosa: a placebo-controlled pilot study,” Journal of Clinical Psychopharmacology, vol. 25, no. 1, pp. 85–88, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Naessén, K. Carlström, B. Byström, Y. Pierre, and A. Lindén Hirschberg, “Effects of an antiandrogenic oral contraceptive on appetite and eating behavior in bulimic women,” Psychoneuroendocrinology, vol. 32, no. 5, pp. 548–554, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. T. M. Barber, F. F. Casanueva, F. Karpe et al., “Ghrelin levels are suppressed and show a blunted response to oral glucose in women with polycystic ovary syndrome,” European Journal of Endocrinology, vol. 158, no. 4, pp. 511–516, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. L. J. Moran, M. Noakes, P. M. Clifton et al., “Ghrelin and measures of satiety are altered in polycystic ovary syndrome but not differentially affected by diet composition,” The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 7, pp. 3337–3344, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. F. Kokot and R. Ficek, “Effects of neuropeptide Y on appetite,” Mineral and Electrolyte Metabolism, vol. 25, no. 4–6, pp. 303–305, 1999. View at Publisher · View at Google Scholar · View at Scopus
  39. B. Baranowska, M. Radzikowska, E. Wasilewska-Dziubińska, A. Kapliński, K. Roguski, and A. Płonowski, “Neuropeptide Y, leptin, galanin and insulin in women with polycystic ovary syndrome,” Gynecological Endocrinology, vol. 13, no. 5, pp. 344–351, 1999. View at Publisher · View at Google Scholar · View at Scopus
  40. S. R. Smith, J. C. Lovejoy, F. Greenway et al., “Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity,” Metabolism: Clinical and Experimental, vol. 50, no. 4, pp. 425–435, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. E. Carmina, S. Bucchieri, A. Esposito et al., “Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance,” Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 7, pp. 2500–2505, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. Z. H. Huang, B. Manickam, V. Ryvkin et al., “PCOS is associated with increased CD11c expression and crown-like structures in adipose tissue and increased central abdominal fat depots independent of obesity,” Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 1, pp. E17–E24, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. E. Fabbrini, F. Magkos, B. S. Mohammed et al., “Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 36, pp. 15430–15435, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. N. Klöting, M. Fasshauer, A. Dietrich et al., “Insulin-sensitive obesity,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 299, no. 3, pp. E506–E515, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. L. Mannerås-Holm, H. Leonhardt, J. Kullberg et al., “Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 2, pp. E304–E311, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. T. M. Barber, S. J. Golding, C. Alvey et al., “Global adiposity rather than abnormal regional fat distribution characterizes women with polycystic ovary syndrome,” The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 3, pp. 999–1004, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. C. Good, M. Tulchinsky, D. Mauger, L. M. Demers, and R. S. Legro, “Bone mineral density and body composition in lean women with polycystic ovary syndrome,” Fertility and Sterility, vol. 72, no. 1, pp. 21–25, 1999. View at Publisher · View at Google Scholar · View at Scopus
  48. J. G. Dolfing, C. M. Stassen, P. M. M. van Haard, B. H. R. Wolffenbuttel, and D. H. Schweitzer, “Comparison of MRI-assessed body fat content between lean women with polycystic ovary syndrome (PCOS) and matched controls: less visceral fat with PCOS,” Human Reproduction, vol. 26, no. 6, pp. 1495–1500, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Kirchengast and J. Huber, “Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome,” Human Reproduction, vol. 16, no. 6, pp. 1255–1260, 2001. View at Publisher · View at Google Scholar · View at Scopus
  50. J. J. Puder, S. Varga, M. Kraenzlin, C. de Geyter, U. Keller, and B. Müller, “Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance,” Journal of Clinical Endocrinology & Metabolism, vol. 90, no. 11, pp. 6014–6021, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. R. A. Wild, E. Carmina, E. Diamanti-Kandarakis et al., “Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the androgen excess and polycystic ovary syndrome (AE-PCOS) society,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 5, pp. 2038–2049, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. D. P. Baldani, L. Skrgatic, M. S. Goldstajn et al., “Clinical and biochemical characteristics of polycystic ovary syndrome in Croatian population,” Collegium Antropologicum, vol. 36, no. 4, pp. 1413–1418, 2012. View at Google Scholar · View at Scopus
  53. A. Gambineri, C. Pelusi, E. Manicardi et al., “Glucose intolerance in a large cohort of Mediterranean women with polycystic ovary syndrome: phenotype and associated factors,” Diabetes, vol. 53, no. 9, pp. 2353–2358, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. C. N. Wijeyaratne, R. D. A. Seneviratne, S. Dahanayake et al., “Phenotype and metabolic profile of South Asian women with polycystic ovary syndrome (PCOS): results of a large database from a specialist Endocrine Clinic,” Human Reproduction, vol. 26, no. 1, pp. 202–213, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. J. C. Lo, S. L. Feigenbaum, J. Yang, A. R. Pressman, J. V. Selby, and A. S. Go, “Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 4, pp. 1357–1363, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. Y. Zhao and J. Qiao, “Ethnic differences in the phenotypic expression of polycystic ovary syndrome,” Steroids, vol. 78, no. 8, pp. 755–760, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. E. Carmina, F. Orio, S. Palomba et al., “Endothelial dysfunction in PCOS: role of obesity and adipose hormones,” The American Journal of Medicine, vol. 119, no. 4, pp. 356.e1–356.e6, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. A. R. Folsom, J. H. Eckfeldt, S. Weitzman et al., “Relation of carotid artery wall thickness to diabetes mellitus, fasting glucose and insulin, body size, and physical activity. Atherosclerosis Risk in Communities (ARIC) Study Investigators,” Stroke, vol. 25, no. 1, pp. 66–73, 1994. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Laakso, H. Sarlund, R. Salonen et al., “Asymptomatic atherosclerosis and insulin resistance,” Arteriosclerosis and Thrombosis, and Vascular Biology, vol. 11, no. 4, pp. 1068–1076, 1991. View at Publisher · View at Google Scholar · View at Scopus
  60. E. O. Talbott, D. S. Guzick, K. Sutton-Tyrrell et al., “Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 11, pp. 2414–2421, 2000. View at Publisher · View at Google Scholar · View at Scopus
  61. F. Orio Jr., S. Palomba, L. Spinelli et al., “The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 8, pp. 3696–3701, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. R. Miccoli, C. Bianchi, G. Penno, and S. del Prato, “Insulin resistance and lipid disorders,” Future Lipidology, vol. 3, no. 6, pp. 651–664, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. J. Slowinska-Srzednicka, S. Zgliczynski, M. Wierzbicki et al., “The role of hyperinsulinemia in the development of lipid disturbances in nonobese and obese women with the polycystic ovary syndrome,” Journal of Endocrinological Investigation, vol. 14, no. 7, pp. 569–575, 1991. View at Publisher · View at Google Scholar · View at Scopus
  64. L.-H. Zhang, H. Rodriguez, S. Ohno, and W. L. Miller, “Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 23, pp. 10619–10623, 1995. View at Publisher · View at Google Scholar · View at Scopus
  65. D. Rosenbaum, R. S. Haber, and A. Dunaif, “Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT-4 glucose transporters in adipocytes,” American Journal of Physiology—Endocrinology and Metabolism, vol. 264, no. 2, part 1, pp. E197–E202, 1993. View at Google Scholar · View at Scopus
  66. A. Corbould, H. Zhao, S. Mirzoeva, F. Aird, and A. Dunaif, “Enhanced mitogenic signaling in skeletal muscle of women with polycystic ovary syndrome,” Diabetes, vol. 55, no. 3, pp. 751–759, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. I. Ek, P. Arner, M. Rydén et al., “A unique defect in the regulation of visceral fat cell lipolysis in the polycystic ovary syndrome as an early link to insulin resistance,” Diabetes, vol. 51, no. 2, pp. 484–492, 2002. View at Publisher · View at Google Scholar · View at Scopus
  68. American Diabetes Association, “Screening for type 2 diabetes,” Diabetes Care, vol. 27, supplement 1, pp. s11–s14, 2014. View at Google Scholar
  69. R. S. Legro, A. R. Kunselman, W. C. Dodson, and A. Dunaif, “Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women,” The Journal of Clinical Endocrinology & Metabolism, vol. 84, no. 1, pp. 165–169, 1999. View at Publisher · View at Google Scholar · View at Scopus
  70. C. Celik, N. Tasdemir, R. Abali, E. Bastu, and M. Yilmaz, “Progression to impaired glucose tolerance or type 2 diabetes mellitus in polycystic ovary syndrome: a controlled follow-up study,” Fertility and Sterility, vol. 101, no. 4, pp. 1123.e1–1128.e1, 2014. View at Publisher · View at Google Scholar · View at Scopus
  71. R. S. Legro, A. R. Kunselman, and A. Dunaif, “Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome,” The American Journal of Medicine, vol. 111, no. 8, pp. 607–613, 2001. View at Publisher · View at Google Scholar · View at Scopus
  72. W. C. Knowler, E. Barrett-Connor, S. E. Fowler et al., “Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin,” The New England Journal of Medicine, vol. 346, no. 6, pp. 393–403, 2002. View at Publisher · View at Google Scholar · View at Scopus
  73. B. C. J. M. Fauser, B. C. Tarlatzis, R. W. Rebar et al., “Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group,” Fertility and Sterility, vol. 97, no. 1, pp. 28.e25–38.e25, 2012. View at Publisher · View at Google Scholar · View at Scopus
  74. N. M. O'Meara, J. D. Blackman, D. A. Ehrmann et al., “Defects in β-cell function in functional ovarian hyperandrogenism,” The Journal of Clinical Endocrinology & Metabolism, vol. 76, no. 5, pp. 1241–1247, 1993. View at Google Scholar · View at Scopus
  75. A. Dunaif and D. T. Finegood, “Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome,” Journal of Clinical Endocrinology & Metabolism, vol. 81, no. 3, pp. 942–947, 1996. View at Publisher · View at Google Scholar · View at Scopus
  76. M. J. Vázquez, A. Romero-Ruiz, and M. Tena-Sempere, “Roles of leptin in reproduction, pregnancy and polycystic ovary syndrome: consensus knowledge and recent developments,” Metabolism, vol. 64, no. 1, pp. 79–91, 2015. View at Publisher · View at Google Scholar
  77. A. M. Wallace, A. D. McMahon, C. J. Packard et al., “Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS),” Circulation, vol. 104, no. 25, pp. 3052–3056, 2001. View at Publisher · View at Google Scholar · View at Scopus
  78. J. D. Knudson, Ü. D. Dincer, C. Zhang et al., “Leptin receptors are expressed in coronary arteries, and hyperleptinemia causes significant coronary endothelial dysfunction,” American Journal of Physiology: Heart and Circulatory Physiology, vol. 289, no. 1, pp. H48–H56, 2005. View at Publisher · View at Google Scholar · View at Scopus
  79. M. P. Reilly, N. Iqbal, M. Schutta et al., “Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes,” Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 8, pp. 3872–3878, 2004. View at Publisher · View at Google Scholar · View at Scopus
  80. P. R. Brzechffa, A. J. Jakimiuk, S. K. Agarwal, S. R. Weitsman, R. P. Buyalos, and D. A. Magoffin, “Serum immunoreactive leptin concentrations in women with polycystic ovary syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 11, pp. 4166–4169, 1996. View at Publisher · View at Google Scholar · View at Scopus
  81. R. Yildizhan, G. A. Ilhan, B. Yildizhan, A. Kolusari, E. Adali, and G. Bugdayci, “Serum retinol-binding protein 4, leptin, and plasma asymmetric dimethylarginine levels in obese and nonobese young women with polycystic ovary syndrome,” Fertility and Sterility, vol. 96, no. 1, pp. 246–250, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. G. Gennarelli, J. Holte, L. Wide, C. Berne, and H. Lithell, “Is there a role for leptin in the endocrine and metabolic aberrations of polycystic ovary syndrome?” Human Reproduction, vol. 13, no. 3, pp. 535–541, 1998. View at Publisher · View at Google Scholar · View at Scopus
  83. S. Hahn, U. Haselhorst, B. Quadbeck et al., “Decreased soluble leptin receptor levels in women with polycystic ovary syndrome,” European Journal of Endocrinology, vol. 154, no. 2, pp. 287–294, 2006. View at Publisher · View at Google Scholar · View at Scopus
  84. M. J. Iuorno, L. Z. Islam, P. P. Veldhuis et al., “Leptin secretory burst mass correlates with body mass index and insulin in normal women but not in women with polycystic ovary syndrome,” Metabolism, vol. 56, no. 11, pp. 1561–1565, 2007. View at Publisher · View at Google Scholar · View at Scopus
  85. C. S. Mantzoros, A. Dunaif, and J. S. Flier, “Leptin concentrations in the polycystic ovary syndrome,” Journal of Clinical Endocrinology & Metabolism, vol. 82, no. 6, pp. 1687–1691, 1997. View at Google Scholar · View at Scopus
  86. I. R. Pirwany, R. Fleming, N. Sattar, I. A. Greer, and A. M. Wallace, “Circulating leptin concentrations and ovarian function in polycystic ovary syndrome,” European Journal of Endocrinology, vol. 145, no. 3, pp. 289–294, 2001. View at Publisher · View at Google Scholar · View at Scopus
  87. J. Rouru, L. Anttila, P. Koskinen et al., “Serum leptin concentrations in women with polycystic ovary syndrome,” The Journal of Clinical Endocrinology & Metabolism, vol. 82, no. 6, pp. 1697–1700, 1997. View at Publisher · View at Google Scholar · View at Scopus
  88. V. P. Sepilian, J. R. Crochet, and M. Nagamani, “Serum soluble leptin receptor levels and free leptin index in women with polycystic ovary syndrome: relationship to insulin resistance and androgens,” Fertility and Sterility, vol. 85, no. 5, pp. 1441–1447, 2006. View at Publisher · View at Google Scholar · View at Scopus
  89. P. F. Svendsen, M. Christiansen, P. L. Hedley, L. Nilas, S. B. Pedersen, and S. Madsbad, “Adipose expression of adipocytokines in women with polycystic ovary syndrome,” Fertility and Sterility, vol. 98, no. 1, pp. 235–241, 2012. View at Publisher · View at Google Scholar · View at Scopus
  90. M. H. Telli, M. Yildirim, and V. Noyan, “Serum leptin levels in patients with polycystic ovary syndrome,” Fertility and Sterility, vol. 77, no. 5, pp. 932–935, 2002. View at Publisher · View at Google Scholar · View at Scopus
  91. X. Chen, X. Jia, J. Qiao, Y. Guan, and J. Kang, “Adipokines in reproductive function: a link between obesity and polycystic ovary syndrome,” Journal of Molecular Endocrinology, vol. 50, no. 2, pp. R21–R37, 2013. View at Publisher · View at Google Scholar · View at Scopus
  92. G. A. Laughlin, A. J. Morales, and S. S. C. Yen, “Serum leptin levels in women with polycystic ovary syndrome: the role of insulin resistance/hyperinsulinemia,” The Journal of Clinical Endocrinology & Metabolism, vol. 82, no. 6, pp. 1692–1696, 1997. View at Google Scholar · View at Scopus
  93. T. Kadowaki, T. Yamauchi, N. Kubota, K. Hara, K. Ueki, and K. Tobe, “Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome,” The Journal of Clinical Investigation, vol. 116, no. 7, pp. 1784–1792, 2006. View at Publisher · View at Google Scholar · View at Scopus
  94. N. Stefan, B. Vozarova, T. Funahashi et al., “Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans,” Diabetes, vol. 51, no. 6, pp. 1884–1888, 2002. View at Publisher · View at Google Scholar · View at Scopus
  95. C. Weyer, T. Funahashi, S. Tanaka et al., “Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 5, pp. 1930–1935, 2001. View at Publisher · View at Google Scholar · View at Scopus
  96. B.-C. Zyriax, P. Algenstaedt, U. F. Hess et al., “Factors contributing to the risk of cardiovascular disease reflected by plasma adiponectin: data from the coronary risk factors for atherosclerosis in women (CORA) study,” Atherosclerosis, vol. 200, no. 2, pp. 403–409, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. M. Lu, Q. Tang, J. M. Olefsky, P. L. Mellon, and N. J. G. Webster, “Adiponectin activates adenosine monophosphate-activated protein kinase and decreases luteinizing hormone secretion in LβT2 gonadotropes,” Molecular Endocrinology, vol. 22, no. 3, pp. 760–771, 2008. View at Publisher · View at Google Scholar · View at Scopus
  98. K. A. Toulis, D. G. Goulis, D. Farmakiotis et al., “Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis,” Human Reproduction Update, vol. 15, no. 3, pp. 297–307, 2009. View at Publisher · View at Google Scholar · View at Scopus
  99. L. Gao, Y. Zhang, Y. Cui, Y. Jiang, X. Wang, and J. Liu, “Association of the T45G and G276T polymorphisms in the adiponectin gene with PCOS: a meta-analysis,” Gynecological Endocrinology, vol. 28, no. 2, pp. 106–110, 2012. View at Publisher · View at Google Scholar · View at Scopus
  100. U. B. Pajvani, M. Hawkins, T. P. Combs et al., “Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity,” The Journal of Biological Chemistry, vol. 279, no. 13, pp. 12152–12162, 2004. View at Publisher · View at Google Scholar · View at Scopus
  101. E. P. Wickham III, K. I. Cheang, J. N. Clore, J.-P. Baillargeon, and J. E. Nestler, “Total and high-molecular weight adiponectin in women with the polycystic ovary syndrome,” Metabolism, vol. 60, no. 3, pp. 366–372, 2011. View at Publisher · View at Google Scholar · View at Scopus
  102. A. Fukuhara, M. Matsuda, M. Nishizawa et al., “Visfatin: a protein secreted by visceral fat that Mimics the effects of insulin,” Science, vol. 307, no. 5708, pp. 426–430, 2005. View at Publisher · View at Google Scholar · View at Scopus
  103. Y.-H. Chang, D.-M. Chang, K.-C. Lin, S.-J. Shin, and Y.-J. Lee, “Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review,” Diabetes/Metabolism Research and Reviews, vol. 27, no. 6, pp. 515–527, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. A. López-Bermejo, B. Chico-Julià, M. Fernàndez-Balsells et al., “Serum visfatin increases with progressive beta-cell deterioration,” Diabetes, vol. 55, no. 10, pp. 2871–2875, 2006. View at Publisher · View at Google Scholar · View at Scopus
  105. D. G. Haider, G. Schaller, S. Kapiotis, C. Maier, A. Luger, and M. Wolzt, “The release of the adipocytokine visfatin is regulated by glucose and insulin,” Diabetologia, vol. 49, no. 8, pp. 1909–1914, 2006. View at Publisher · View at Google Scholar · View at Scopus
  106. B. K. Tan, J. Chen, S. Farhatullah et al., “Insulin and metformin regulate circulating and adipose tissue chemerin,” Diabetes, vol. 58, no. 9, pp. 1971–1977, 2009. View at Publisher · View at Google Scholar · View at Scopus
  107. I. Kowalska, M. Straczkowski, A. Nikolajuk et al., “Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome,” Human Reproduction, vol. 22, no. 7, pp. 1824–1829, 2007. View at Publisher · View at Google Scholar · View at Scopus
  108. B. Zahorska-Markiewicz, M. Olszanecka-Glinianowicz, J. Janowska et al., “Serum concentration of visfatin in obese women,” Metabolism: Clinical and Experimental, vol. 56, no. 8, pp. 1131–1134, 2007. View at Publisher · View at Google Scholar · View at Scopus
  109. K. Takebayashi, M. Suetsugu, S. Wakabayashi, Y. Aso, and T. Inukai, “Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus,” Metabolism: Clinical and Experimental, vol. 56, no. 4, pp. 451–458, 2007. View at Publisher · View at Google Scholar · View at Scopus
  110. R. Adya, B. K. Tan, J. Chen, and H. S. Randeva, “Nuclear factor-κb induction by visfatin in human vascular endothelial cells,” Diabetes Care, vol. 31, no. 4, pp. 758–760, 2008. View at Publisher · View at Google Scholar · View at Scopus
  111. Y. Fan, S. Meng, Y. Wang, J. Cao, and C. Wang, “Visfatin/PBEF/Nampt induces EMMPRIN and MMP-9 production in macrophages via the NAMPT-MAPK (p38, ERK1/2)-NF-κB signaling pathway,” International Journal of Molecular Medicine, vol. 27, no. 4, pp. 607–615, 2011. View at Publisher · View at Google Scholar · View at Scopus
  112. T. B. Dahl, A. Yndestad, M. Skjelland et al., “Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization,” Circulation, vol. 115, no. 8, pp. 972–980, 2007. View at Publisher · View at Google Scholar · View at Scopus
  113. T.-F. Chan, Y.-L. Chen, H.-H. Chen, C.-H. Lee, S.-B. Jong, and E.-M. Tsai, “Increased plasma visfatin concentrations in women with polycystic ovary syndrome,” Fertility and Sterility, vol. 88, no. 2, pp. 401–405, 2007. View at Publisher · View at Google Scholar · View at Scopus
  114. M. Ozkaya, E. Cakal, Y. Ustun, and Y. Engin-Ustun, “Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome,” Fertility and Sterility, vol. 93, no. 3, pp. 880–884, 2010. View at Publisher · View at Google Scholar · View at Scopus
  115. D. Panidis, D. Farmakiotis, D. Rousso et al., “Plasma visfatin levels in normal weight women with polycystic ovary syndrome,” European Journal of Internal Medicine, vol. 19, no. 6, pp. 406–412, 2008. View at Publisher · View at Google Scholar · View at Scopus
  116. K.-M. Seow, J.-L. Hwang, P.-H. Wang, L.-T. Ho, and C.-C. Juan, “Expression of visfatin mRNA in peripheral blood mononuclear cells is not correlated with visfatin mRNA in omental adipose tissue in women with polycystic ovary syndrome,” Human Reproduction, vol. 26, no. 10, pp. 2869–2873, 2011. View at Publisher · View at Google Scholar · View at Scopus
  117. T. K. Lajunen, A.-K. Purhonen, M. Haapea et al., “Full-length visfatin levels are associated with inflammation in women with polycystic ovary syndrome,” European Journal of Clinical Investigation, vol. 42, no. 3, pp. 321–328, 2012. View at Publisher · View at Google Scholar · View at Scopus
  118. M. Olszanecka-Glinianowicz, P. Madej, D. Zdun et al., “Are plasma levels of visfatin and retinol-binding protein 4 (RBP4) associated with body mass, metabolic and hormonal disturbances in women with polycystic ovary syndrome?” European Journal of Obstetrics Gynecology & Reproductive Biology, vol. 162, no. 1, pp. 55–61, 2012. View at Publisher · View at Google Scholar · View at Scopus
  119. K. Bozaoglu, K. Bolton, J. McMillan et al., “Chemerin is a novel adipokine associated with obesity and metabolic syndrome,” Endocrinology, vol. 148, no. 10, pp. 4687–4694, 2007. View at Publisher · View at Google Scholar · View at Scopus
  120. H. Sell, J. Laurencikiene, A. Taube et al., “Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells,” Diabetes, vol. 58, no. 12, pp. 2731–2740, 2009. View at Publisher · View at Google Scholar · View at Scopus
  121. S.-G. Roh, S.-H. Song, K.-C. Choi et al., “Chemerin—a new adipokine that modulates adipogenesis via its own receptor,” Biochemical and Biophysical Research Communications, vol. 362, no. 4, pp. 1013–1018, 2007. View at Publisher · View at Google Scholar · View at Scopus
  122. B. A. Zabel, S. J. Allen, P. Kulig et al., “Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades,” The Journal of Biological Chemistry, vol. 280, no. 41, pp. 34661–34666, 2005. View at Publisher · View at Google Scholar · View at Scopus
  123. E. C. Guzel, C. Celik, R. Abali et al., “Omentin and chemerin and their association with obesity in women with polycystic ovary syndrome,” Gynecological Endocrinology, vol. 30, no. 6, pp. 419–422, 2014. View at Publisher · View at Google Scholar · View at Scopus
  124. C. N. Lumeng and A. R. Saltiel, “Inflammatory links between obesity and metabolic disease,” Journal of Clinical Investigation, vol. 121, no. 6, pp. 2111–2117, 2011. View at Publisher · View at Google Scholar · View at Scopus
  125. J. M. Wentworth, G. Naselli, W. A. Brown et al., “Pro-inflammatory CD11c+CD206+ adipose tissue macrophages are associated with insulin resistance in human obesity,” Diabetes, vol. 59, no. 7, pp. 1648–1656, 2010. View at Publisher · View at Google Scholar · View at Scopus
  126. G. S. Hotamisligil, A. Budavari, D. Murray, and B. M. Spiegelman, “Reduced tyrosine kinase activity of the insulin receptor in obesity- diabetes. Central role of tumor necrosis factor-alpha,” Journal of Clinical Investigation, vol. 94, no. 4, pp. 1543–1549, 1994. View at Publisher · View at Google Scholar · View at Scopus
  127. J. M. Stephens and P. H. Pekala, “Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-α,” The Journal of Biological Chemistry, vol. 266, no. 32, pp. 21839–21845, 1991. View at Google Scholar · View at Scopus
  128. H. F. Escobar-Morreale, R. M. Calvo, G. Villuendas, J. Sancho, and J. L. San Millán, “Association of polymorphisms in the interleukin 6 receptor complex with obesity and hyperandrogenism,” Obesity Research, vol. 11, no. 8, pp. 987–996, 2003. View at Publisher · View at Google Scholar · View at Scopus
  129. N. C. Sayin, F. Gücer, P. Balkanli-Kaplan et al., “Elevated serum TNF-alpha levels in normal-weight women with polycystic ovaries or the polycystic ovary syndrome,” The Journal of Reproductive Medicine, vol. 48, no. 3, pp. 165–170, 2003. View at Google Scholar · View at Scopus
  130. B. Peral, J. L. San Millán, R. Castello, P. Moghetti, and H. F. Escobar-Morreale, “The methionine 196 arginine polymorphism in exon 6 of the TNF receptor 2 gene (TNFRSF1B) is associated with the polycystic ovary syndrome and hyperandrogenism,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 8, pp. 3977–3983, 2002. View at Publisher · View at Google Scholar · View at Scopus
  131. J. Danesh, J. G. Wheeler, G. M. Hirschfield et al., “C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease,” The New England Journal of Medicine, vol. 350, no. 14, pp. 1387–1397, 2004. View at Publisher · View at Google Scholar · View at Scopus
  132. P. M. Ridker, C. H. Hennekens, J. E. Buring, and N. Rifai, “C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women,” The New England Journal of Medicine, vol. 342, no. 12, pp. 836–843, 2000. View at Publisher · View at Google Scholar · View at Scopus
  133. J. S. Yudkin, C. D. A. Stehouwer, J. J. Emeis, and S. W. Coppack, “C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 4, pp. 972–978, 1999. View at Publisher · View at Google Scholar · View at Scopus
  134. B. Vozarova, J.-M. Fernández-Real, W. C. Knowler et al., “The interleukin-6 (-174) G/C promoter polymorphism is associated with type-2 diabetes mellitus in Native Americans and Caucasians,” Human Genetics, vol. 112, no. 4, pp. 409–413, 2003. View at Google Scholar · View at Scopus
  135. M. Erdogan, M. Karadeniz, A. Berdeli, G. Alper, O. Caglayan, and C. Yilmaz, “The relationship of the interleukin-6 -174 G>C gene polymorphism with oxidative stress markers in Turkish polycystic ovary syndrome patients,” Journal of Endocrinological Investigation, vol. 31, no. 7, pp. 624–629, 2008. View at Publisher · View at Google Scholar · View at Scopus
  136. G. Villuendas, J. L. San Millán, J. Sancho, and H. F. Escobar-Morreale, “The −597 GA and −174 GC polymorphisms in the promoter of the IL-6 gene are associated with hyperandrogenism,” Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 3, pp. 1134–1141, 2002. View at Publisher · View at Google Scholar · View at Scopus
  137. H. F. Escobar-Morreale, G. Villuendas, J. I. Botella-Carretero, J. Sancho, and J. L. San Millán, “Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women,” Diabetologia, vol. 46, no. 5, pp. 625–633, 2003. View at Google Scholar · View at Scopus
  138. S. Sam and A. Dunaif, “Polycystic ovary syndrome: syndrome XX?” Trends in Endocrinology & Metabolism, vol. 14, no. 8, pp. 365–370, 2003. View at Publisher · View at Google Scholar · View at Scopus
  139. M. J. Graf, C. J. Richards, V. Brown, L. Meissner, and A. Dunaif, “The independent effects of hyperandrogenaemia, hyperinsulinaemia, and obesity on lipid and lipoprotein profiles in women,” Clinical Endocrinology, vol. 33, no. 1, pp. 119–131, 1990. View at Publisher · View at Google Scholar · View at Scopus
  140. S. Sam, R. S. Legro, R. Bentley-Lewis, and A. Dunaif, “Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 8, pp. 4797–4802, 2005. View at Publisher · View at Google Scholar · View at Scopus
  141. E. Talbott, A. Clerici, S. L. Berga et al., “Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study,” Journal of Clinical Epidemiology, vol. 51, no. 5, pp. 415–422, 1998. View at Publisher · View at Google Scholar · View at Scopus
  142. R. A. Wild, M. Rizzo, S. Clifton, and E. Carmina, “Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis,” Fertility and Sterility, vol. 95, no. 3, pp. 1073.e11–1079.e11, 2011. View at Publisher · View at Google Scholar · View at Scopus
  143. R. A. Wild, P. C. Painter, P. B. Coulson, K. B. Carruth, and G. B. Ranney, “Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 61, no. 5, pp. 946–951, 1985. View at Publisher · View at Google Scholar · View at Scopus
  144. J. Joharatnam, T. M. Barber, L. Webber, G. S. Conway, M. I. McCarthy, and S. Franks, “Determinants of dyslipidaemia in probands with polycystic ovary syndrome and their sisters,” Clinical Endocrinology, vol. 74, no. 6, pp. 714–719, 2011. View at Publisher · View at Google Scholar · View at Scopus
  145. K. M. Bass, C. J. Newschaffer, M. J. Klag, and T. L. Bush, “Plasma lipoprotein levels as predictors of cardiovascular death in women,” Archives of Internal Medicine, vol. 153, no. 19, pp. 2209–2216, 1993. View at Publisher · View at Google Scholar · View at Scopus
  146. C. J. Glueck, J. A. Morrison, N. Goldenberg, and P. Wang, “Coronary heart disease risk factors in adult premenopausal white women with polycystic ovary syndrome compared with a healthy female population,” Metabolism, vol. 58, no. 5, pp. 714–721, 2009. View at Publisher · View at Google Scholar · View at Scopus
  147. P. A. Essah, J. E. Nestler, and E. Carmina, “Differences in dyslipidemia between American and Italian women with polycystic ovary syndrome,” Journal of Endocrinological Investigation, vol. 31, no. 1, pp. 35–41, 2008. View at Publisher · View at Google Scholar · View at Scopus
  148. K. Berneis, M. Rizzo, M. Hersberger et al., “Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome,” International Journal of Clinical Practice, vol. 63, no. 1, pp. 56–62, 2009. View at Publisher · View at Google Scholar · View at Scopus
  149. M. Rajkhowa, R. H. Neary, P. Kumpatla et al., “Altered composition of high density lipoproteins in women with the polycystic ovary syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 10, pp. 3389–3394, 1997. View at Publisher · View at Google Scholar · View at Scopus
  150. Y. Arad, L. A. Spadaro, K. Goodman, D. Newstein, and A. D. Guerci, “Prediction of coronary events with electron beam computed tomography,” Journal of the American College of Cardiology, vol. 36, no. 4, pp. 1253–1260, 2000. View at Publisher · View at Google Scholar · View at Scopus
  151. R. C. Christian, D. A. Dumesic, T. Behrenbeck, A. L. Oberg, P. F. Sheedy II, and L. A. Fitzpatrick, “Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 6, pp. 2562–2568, 2003. View at Publisher · View at Google Scholar · View at Scopus
  152. R. Shroff, A. Kerchner, M. Maifeld, E. J. R. van Beek, D. Jagasia, and A. Dokras, “Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 12, pp. 4609–4614, 2007. View at Publisher · View at Google Scholar · View at Scopus
  153. E. O. Talbott, J. V. Zborowski, J. R. Rager, M. Y. Boudreaux, D. A. Edmundowicz, and D. S. Guzick, “Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome,” The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 11, pp. 5454–5461, 2004. View at Publisher · View at Google Scholar · View at Scopus
  154. A. Elisabeth Hak, J. C. M. Witteman, F. H. De Jong, M. I. Geerlings, A. Hofman, and H. A. P. Pols, “Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam Study,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 8, pp. 3632–3639, 2002. View at Publisher · View at Google Scholar · View at Scopus
  155. M. W. Lorenz, H. S. Markus, M. L. Bots, M. Rosvall, and M. Sitzer, “Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis,” Circulation, vol. 115, no. 4, pp. 459–467, 2007. View at Publisher · View at Google Scholar · View at Scopus
  156. M. Luque-Ramírez, C. Mendieta-Azcona, F. Álvarez-Blasco, and H. F. Escobar-Morreale, “Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome,” Human Reproduction, vol. 22, no. 12, pp. 3197–3203, 2007. View at Publisher · View at Google Scholar · View at Scopus
  157. M. L. Meyer, A. M. Malek, R. A. Wild, M. T. Korytkowski, and E. O. Talbott, “Carotid artery intima-media thickness in polycystic ovary syndrome: a systematic review and meta-analysis,” Human Reproduction Update, vol. 18, no. 2, pp. 112–126, 2012. View at Publisher · View at Google Scholar · View at Scopus
  158. G. Paradisi, H. O. Steinberg, A. Hempfling et al., “Polycystic ovary syndrome is associated with endothelial dysfunction,” Circulation, vol. 103, no. 10, pp. 1410–1415, 2001. View at Publisher · View at Google Scholar · View at Scopus
  159. S. Mark Herman, J. T. C. Robinson, R. J. McCredie, M. R. Adams, M. J. Boyer, and D. S. Celermajer, “Androgen deprivation is associated with enhanced endothelium-dependent dilatation in adult men,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 10, pp. 2004–2009, 1997. View at Publisher · View at Google Scholar · View at Scopus
  160. M. Murri, M. Luque-ramírez, M. Insenser, M. Ojeda-ojeda, and H. F. Escobar-morreale, “Circulating markers of oxidative stress and polycystic ovary syndrome (pcos): a systematic review and meta-analysis,” Human Reproduction Update, vol. 19, no. 3, Article ID dms059, pp. 268–288, 2013. View at Publisher · View at Google Scholar · View at Scopus
  161. I. F. W. McDowell and D. Lang, “Homocysteine and endothelial dysfunction: a link with cardiovascular disease,” Journal of Nutrition, vol. 130, supplement 2, pp. 369S–372S, 2000. View at Google Scholar · View at Scopus
  162. T. G. DeLoughery, “Coagulation abnormalities and cardiovascular disease,” Current Opinion in Lipidology, vol. 10, no. 5, pp. 443–448, 1999. View at Publisher · View at Google Scholar · View at Scopus
  163. B. O. Yildiz, C. Haznedaroglu, E. Kirazli, and M. Bayraktar, “Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 8, pp. 3871–3875, 2002. View at Publisher · View at Google Scholar · View at Scopus
  164. L. J. Moran, S. K. Hutchison, C. Meyer, S. Zoungas, and H. J. Teede, “A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome,” Clinical Science (Lond), vol. 116, no. 10, pp. 761–770, 2009. View at Publisher · View at Google Scholar · View at Scopus
  165. S. Rajendran, S. R. Willoughby, W. P. A. Chan et al., “Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects,” Atherosclerosis, vol. 204, no. 2, pp. 509–514, 2009. View at Publisher · View at Google Scholar · View at Scopus
  166. L. Manneras-Holm, F. Baghaei, G. Holm et al., “Coagulation and fibrinolytic disturbances in women with polycystic ovary syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 4, pp. 1068–1076, 2011. View at Publisher · View at Google Scholar · View at Scopus
  167. M. E. Stegenga, S. N. Van Der Crabben, M. Levi et al., “Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans,” Diabetes, vol. 55, no. 6, pp. 1807–1812, 2006. View at Publisher · View at Google Scholar · View at Scopus
  168. D. P. Baldani, L. Skrgatic, J. Z. Cerne, S. K. Oguic, B. M. Gersak, and K. Gersak, “Association between serum levels and pentanucleotide polymorphism in the sex hormone binding globulin gene and cardiovascular risk factors in females with polycystic ovary syndrome,” Molecular Medicine Reports, vol. 11, no. 5, pp. 3941–3947, 2015. View at Publisher · View at Google Scholar
  169. M. B. Tíraš, R. Yalçìn, V. Noyan et al., “Alterations in cardiac flow parameters in patients with polycystic ovarian syndrome,” Human Reproduction, vol. 14, no. 8, pp. 1949–1952, 1999. View at Publisher · View at Google Scholar · View at Scopus
  170. T. Pierpoint, P. M. McKeigue, A. J. Isaacs, S. H. Wild, and H. S. Jacobs, “Mortality of women with polycystic ovary syndrome at long-term follow-up,” Journal of Clinical Epidemiology, vol. 51, no. 7, pp. 581–586, 1998. View at Publisher · View at Google Scholar · View at Scopus
  171. J. Schmidt, M. Brännström, K. Landin-Wilhelmsen, and E. Dahlgren, “Reproductive hormone levels and anthropometry in postmenopausal women with polycystic ovary syndrome (PCOS): a 21-year follow-up study of women diagnosed with PCOS around 50 years ago and their age-matched controls,” The Journal of Clinical Endocrinology & Metabolism, vol. 96, no. 7, pp. 2178–2185, 2011. View at Publisher · View at Google Scholar · View at Scopus
  172. S. Wild, T. Pierpoint, P. McKeigue, and H. Jacobs, “Cardiovascular disease in women with polycystic ovary syndrome at long- term follow-up: a retrospective cohort study,” Clinical Endocrinology, vol. 52, no. 5, pp. 595–600, 2000. View at Publisher · View at Google Scholar · View at Scopus
  173. C. G. Solomon, F. B. Hu, A. Dunaif et al., “Menstrual cycle irregularity and risk for future cardiovascular disease,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 5, pp. 2013–2017, 2002. View at Publisher · View at Google Scholar · View at Scopus
  174. P. C. M. de Groot, O. M. Dekkers, J. A. Romijn, S. W. M. Dieben, and F. M. Helmerhorst, “PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis,” Human Reproduction Update, vol. 17, no. 4, pp. 495–500, 2011. View at Publisher · View at Google Scholar · View at Scopus
  175. L. J. Shaw, C. N. B. Merz, R. Azziz et al., “Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health-National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation,” The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 4, pp. 1276–1284, 2008. View at Publisher · View at Google Scholar · View at Scopus
  176. H. Mani, M. J. Levy, M. J. Davies et al., “Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20-year retrospective cohort study,” Clinical Endocrinology, vol. 78, no. 6, pp. 926–934, 2013. View at Publisher · View at Google Scholar · View at Scopus